Get the Stockscreener App
7.32
4.44%
-0.34
After Hours:
7.34
0.02
+0.27%
Mersana Therapeutics Inc stock is traded at $7.32, with a volume of 40,654.
It is down -4.44% in the last 24 hours and up +5.32% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$7.66
Open:
$7.78
24h Volume:
40,654
Relative Volume:
0.37
Market Cap:
$36.53M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-0.9266
EPS:
-7.9
Net Cash Flow:
$-79.76M
1W Performance:
-5.55%
1M Performance:
+5.32%
6M Performance:
-41.78%
1Y Performance:
-80.74%
1-Day Range:
$7.315
$7.85
1-Week Range:
$7.315
$8.09
52-Week Range:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.32 | 38.23M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Can Mersana Therapeutics Inc. stock double in the next yearJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - خودرو بانک
Can Mersana Therapeutics Inc. reach resistance levels soon2025 Technical Patterns & Real-Time Volume Analysis - خودرو بانک
What does recent volatility data suggest for Mersana Therapeutics Inc.July 2025 Movers & Daily Stock Trend Reports - Newser
What recovery options are there for Mersana Therapeutics Inc.Quarterly Growth Report & Fast Entry Momentum Trade Alerts - Newser
Is Mersana Therapeutics Inc. stock reversal real or fake2025 Momentum Check & Real-Time Market Trend Scan - Newser
Is Mersana Therapeutics Inc. subject to activist investor interestAnalyst Downgrade & Weekly Momentum Picks - خودرو بانک
How does Mersana Therapeutics Inc. perform in inflationary periods2025 Key Lessons & Daily Price Action Insights - خودرو بانک
Evaluating Mersana Therapeutics Inc. with trendline analysisPortfolio Growth Summary & High Accuracy Swing Entry Alerts - Newser
Analyzing net buyer seller activity in Mersana Therapeutics Inc.Portfolio Value Summary & Low Risk High Reward Trade Ideas - Newser
Signal strength of Mersana Therapeutics Inc. stock in tech scannersAnalyst Downgrade & Weekly Setup with ROI Potential - Newser
Best data tools to analyze Mersana Therapeutics Inc. stockGold Moves & Precise Entry and Exit Recommendations - Newser
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionWeekly Gains Report & Reliable Intraday Trade Plans - Newser
Can momentum traders help lift Mersana Therapeutics Inc.July 2025 Reactions & High Conviction Investment Ideas - Newser
Can Mersana Therapeutics Inc. recover in the next quarterJuly 2025 Institutional & Weekly Breakout Watchlists - Newser
Developing predictive dashboards with Mersana Therapeutics Inc. data2025 Price Momentum & Advanced Technical Signal Analysis - Newser
Has Mersana Therapeutics Inc. formed a bullish divergenceJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Is Mersana Therapeutics Inc. reversing from oversold territoryJuly 2025 Patterns & Intraday High Probability Setup Alerts - Newser
Mersana Therapeutics Inc. stock volume spike explainedEarnings Growth Report & Real-Time Chart Breakout Alerts - Newser
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Will Mersana Therapeutics Inc. outperform the marketBond Market & Weekly Momentum Stock Picks - Newser
Will Mersana Therapeutics Inc. stock go up soon2025 Investor Takeaways & Safe Entry Momentum Tips - Newser
Using data tools to time your Mersana Therapeutics Inc. exitTrend Reversal & Reliable Entry Point Trade Alerts - Newser
Is it too late to sell Mersana Therapeutics Inc.July 2025 Retail & Verified Short-Term Plans - Newser
Order flow analysis tools used on Mersana Therapeutics Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
What Fibonacci levels say about Mersana Therapeutics Inc. reboundWeekly Stock Recap & Consistent Growth Stock Picks - Newser
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet - MSN
What data driven models say about Mersana Therapeutics Inc.’s futureEntry Point & High Return Stock Watch Alerts - Newser
Will Mersana Therapeutics Inc. bounce back from current support2025 Analyst Calls & Reliable Volume Spike Alerts - Newser
Mersana Therapeutics Inc.’s volatility index tracking explainedAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Chart overlay techniques for tracking Mersana Therapeutics Inc.2025 Market WrapUp & Safe Capital Growth Tips - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via tools2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Full technical analysis of Mersana Therapeutics Inc. stock2025 AllTime Highs & Reliable Trade Execution Plans - Newser
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):